Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Post by blackascanbeon Sep 13, 2011 2:17pm
355 Views
Post# 19037605

in the past week

in the past weeki listened to the two Nuvo presentations at the sept 8 and sept 13 health care conferences as well as the covidien investor presentation. From the Covidien presentation, Covidien is committed to Pennsaid. They want to expand their pain medication portfolio and they see pennsaid and exalgo as a foundation for that effort. John London said today that weekly scripts for pennsaid reached a record for the week ending Sept 2. Also wf10 looks like it could have multiple applications including for oncology, they are currently in the process of solidifying the intellectual property rights and expect to announce a commercial strategy by year end. 
Bullboard Posts